Artelo BIOSCIENCES, Inc. (ARTL) intrinsic value & 10-year financials
Artelo BIOSCIENCES, Inc. (ARTL) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.70
- Market cap
- $2.8M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 2.6%
- Free cash flow (FY2025)
- —
ARTL 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$12.9M | -$12.52 | — | — | 1817.4% |
| FY2024 | — | -$9.8M | -$3.05 | — | — | -212.2% |
| FY2023 | — | -$9.3M | -$3.14 | — | — | -92.5% |
| FY2022 | — | -$10.1M | — | — | — | -114.2% |
| FY2021 | — | -$7.4M | — | — | — | -135.8% |
| FY2020 | — | -$4.7M | — | — | — | -100.4% |
| FY2019 | — | -$2.2M | -$1.46 | — | — | -120.5% |
| FY2018 | — | -$2.3M | -$1.84 | — | — | -1143.5% |
| FY2017 | — | -$234.9K | — | — | — | -87.7% |
| FY2016 | — | -$29.7K | — | — | — | 215.1% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ARTELO BIOSCIENCES, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
ARTELO BIOSCIENCES, INC. has historically struggled to out-earn its cost of capital, averaging just -64.4% ROIC.
ARTELO BIOSCIENCES, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
ARTELO BIOSCIENCES, INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.